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CHAPTER 1
INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin,
ibuprofen, and naproxen, are widely used to reduce pain, fever, and headaches
associated with inflammation. The therapeutic benefits of these drugs are
associated with the inhibition of cyclooxygenases 1 and 2 (COX-1 and COX-2).
Of the two forms, COX-1 is the constitutively active isoform and is responsible for
converting arachidonic acid into prostaglandins that are generally accepted to be
“house-keeping” prostaglandins. COX-2 is the inducible part of the pathway that
is responsible for converting arachidonic acid into inflammatory prostaglandins
that result in pain, swelling, redness, and other inflammatory responses.
Traditional NSAIDs non-specifically inhibit COX-1 and COX-2, meaning they
inhibit both the inflammatory and house-keeping sides of the COX pathway. The
non-specific nature of NSAIDs results in adverse effects that come about as a
consequence of inhibiting the COX-1 pathway. The most noted adverse effects of
COX-1 inhibition are gastric complications that result from the disruption of
prostaglandin E2 production [1]. These gastric complications resulted in a
population of patients who could not tolerate traditional NSAID use. These
patients needed an alternative medication that could offer the anti-inflammatory
properties of NSAIDs without the gastric complications.
1
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Coxibs were developed to meet the need of patients who could not
tolerate traditional NSAID use. Coxibs specifically inhibit the inflammatory COX-2
pathway while leaving the COX-1 pathway relatively unaffected. This was meant
to give patients the anti-inflammatory benefits of blocking the COX-2 pathway
without the gastric complications associated with traditional NSAID use. The
coxibs originally developed were celecoxib (Celebrex®), rofecoxib (Vioxx®),
valdecoxib, etoricoxib, and lumiracoxib. The coxibs were available on the market
just 5 years after animal model validation in 1994, making it one of the most rapid
drug discovery and development efforts [2]. The need for these drugs was
validated when celecoxib and rofecoxib garnered a combined sales total of
almost 2 billion dollars in their first years on the market [2]. This initial success
lead to an aggressive advertising campaign for both drugs. The advertising
exposed many more people to a class of drugs that was originally developed for
patients who could not tolerate traditional NSAIDs. This upsurge in popularity of
coxibs lead to the launch of clinical trials that would add to the labeled uses of
these drugs. One of these clinical trials was the Adenomatous Polyp Prevention
on Vioxx (APPROVE) [2]. During this and two parallel trials, patients on
rofecoxib were found to have an almost 2-fold increase in the occurrence of
cardiovascular side effects; these side effects included myocardial infarctions
and ischemic cerebrovascular events [3-5]. These findings caused Merck to
withdraw Vioxx from the market within days of the report being released. The
following year, valdecoxib was withdrawn from the market for similar reasons [2].
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The negative publicity associated with the withdrawal of rofecoxib and valdecoxib
from the market led to a push to determine the cardiovascular risk profiles of
celecoxib (Celebrex®) and other coxibs still on the market.
A review of randomized clinical trials of COX inhibitors revealed that
rofecoxib and diclofenac both significantly increased the risk of cardiovascular
events [3], but a number of clinical trials were unable to establish the same
increased cardiovascular risk with celecoxib [3, 6]. The mechanism behind this
difference in cardiovascular risk is still unknown and the exact reason behind this
difference is widely debated. Several studies reported celecoxib to exhibit
vasorelaxant effects [7, 8] which may account for its differential risk profile
compared to other COX-2 inhibitors. Our laboratory attempted to explore the
mechanisms behind the vasodilatory actions and lower CV risk for celecoxib by
examining the effects of celecoxib and other NSAIDs on vascular smooth muscle
ion channels. Brueggemann et al. focused their attention on two types of ion
channels that are important in determining the contractile state of vascular
smooth muscle cells (VSMCs): KCNQ (Kv7 family) potassium channels that
determine the resting membrane voltage and L-type voltage gated calcium
channels, the activation of which induces calcium ion influx, smooth muscle
contraction, and vasoconstriction [9]. In that study, our laboratory provided
evidence that celecoxib, but not rofecoxib or diclofenac, activated Kv7 potassium
channels and inhibited L-type calcium channels at comparable therapeutic
concentrations, promoting vasorelaxation and decreasing vascular tone.
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Celecoxib’s ability to modulate these ion channels was also found to be
independent of its COX-2 inhibitory effects. A celecoxib analog, 2,5dimethylcelecoxib (DMC) which does not inhibit COX-2, mimicked both
celecoxib’s activation of Kv7 channels and inhibition of L-type channels [9]. That
study ultimately led to the hypothesis that the COX-2 independent ion channel
modulatory actions of celecoxib may account for the reduced cardiovascular risk
in patients taking celecoxib compared to other coxibs.
The mechanism that underlies celecoxib’s ion channel modulatory actions
is still not known. As stated previously, it is believed that these actions are
independent of celecoxib’s COX-2 inhibitory activity [9]. Given the differential ion
channel modulatory activities reported for celecoxib and rofecoxib, it stands to
reason that the mechanism by which celecoxib activates Kv7 potassium
channels would be stimulated by celecoxib and not by rofecoxib. One such
mechanism is cyclic nucleotide phosphodiesterase (PDE) inhibition. Klein et al.
reported that celecoxib and not rofecoxib, inhibited the PDE4 isoform, which
specifically degrades cyclic adenosine monophosphate (cAMP) [8]. cAMPspecific cyclic nucleotide PDE inhibition results in higher cellular levels of cAMP
which goes on to affect many downstream targets. One well known target of
cAMP is protein kinase A (PKA). Activation of PKA by cAMP leads to the
phosphorylation and activation of many downstream targets, one of which may
be Kv7 potassium channels. In this thesis, I hypothesize that activation of the
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cAMP/PKA pathway is necessary and sufficient to induce the activation of Kv7
potassium channels in vascular smooth muscle cells.

CHAPTER 2
REVIEW OF RELEVANT LITERATURE
KCNQ Channels
Discovery
Kv7 potassium channel subunits are encoded by five genes (KCNQ1-5)
that were first cloned in the 1990s. The Kv7 nomenclature given to this family of
channels was based on the deducted phylogenetic relationships [10] and is used
interchangeably with KCNQ based on the Human Genome Organization’s KCN
nomenclature [11].
KCNQ1 was the first of the Kv7 channels to be discovered. It was
originally named KvLQT1 because it was discovered in the heart and was found
to co-assemble with MinK (which is encoded by the KCNE gene) to form slowly
activating delayed-rectifier K+ channels (IKs) whose dysfunction results in longQT syndrome which can result in fatal cardiac arrhythmias. IKs currents
modulate repolarization of cardiac action potentials [12].
M-currents in the brain are responsible for regulating the subthreshold
excitability of neurons. KCNQ2 and KCNQ3’s properties were determined and it
was reported that the hetero-tetramerization of those two channel subunits is
what underlies neuronal M-current. This conclusion was reached because of their
kinetic properties, which were similar to previously recorded native M-currents,
6
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and their sensitivity to muscarinic inhibition (where the M in M-current is derived)
[13].
To date, KCNQ1-5 (which encode Kv7.1-7.5 channel subunits
respectively) have all been cloned and the channels formed by these subunits
have important functions in many types of excitable tissues [14].

Structure and composition of functional channels
The functional Kv7 channels resemble other Kv channels in that they are
composed of homo- or hetero-tetramers of six transmembrane spanning (S1-S6)
subunits [14]. The P-loop (single pore loop) formed between the S5 and S6
domains form the selectivity filter of the pore. The S4 domain consists of
positively charged arginine residues and acts as a voltage sensor. Both the Nand C-terminus of the channel are present on the cytoplasmic side of the
membrane. A distinct feature of Kv7 channels is that they have a long
intracellular C-terminus [15]. The C-terminus contains a distinctive A-domain that
determines the subunit specificity of the channels [16]. This distinctive Cterminus is important for channel gating, assembly, and trafficking [17].
The five channel subunits can assemble in a number of conformations.
First, each channel is able to form a homo-tetramer which consists of four of the
same alpha subunits. These channel subunits can also form hetero-tetramers,
but the subunit combinations are limited. Kv7.1 is unable to form a heterotetramer with any of the other Kv7 channel subunits, but it has been suggested
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that it co-assembles with KCNE1 which encodes the ancillary protein MinK [18].
Kv7.2 and Kv7.3 form a hetero-tetramer that underlies the M-current of the brain
[13]. Kv7.4 can form a hetero-tetramer with Kv7.3 but not Kv7.2 or Kv7.1 [19, 20].
Kv7.5 can form a hetero-tetramer with Kv7.3 and Kv7.4 but not Kv7.2 [21, 22].
To date, there is no evidence of Kv7 channel subunits assembling with
any other Kv channel subunits (such as Kv1, Kv2, or Kv4).

Expression
Originally, Kv7 channels were thought to be expressed only in neurons
and cardiac myocytes, however, more recent evidence suggests a ubiquitous
expression profile [23, 24]. Additionally, channel expression and assembly varies
by tissue.
In the heart, Kv7.1 channel subunits form homo-tetramers that conduct the
cardiac delayed rectifier current, IKs. This current is responsible for modulating
cardiac repolarization. These Kv7.1 channels have been reported to co-assemble
with MinK which is a single transmembrane spanning auxiliary β-subunit encoded
by the KCNE1 gene. Assembly of MinK with KV7.1 channel subunits leads to
slowing of Kv7.1 activation, an increase in unitary conductance, removal of
inactivation, and an altered regulation and pharmacology of the complex [18].
Mutations in either KCNQ1 or KCNE1 genes can result in long QT syndrome
(LQTS).
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A study by Oliveras et al. suggested the formation of functional
heteromeric complexes between Kv7.5 and Kv7.1 channels (possibly with
KCNE1 and/or KCNE3 regulatory subunits) within the vasculature. This
conclusion was based on the ability of Kv7.1, Kv7.5 and KCNE1 to coimmunoprecipitate in rat aorta myocytes. They also observed Kv7.1 and Kv7.5
forming functional channels with distinct biophysical and pharmacological
properties in an expression system [25]. However, the functionality of Kv7.1
channels in arterial myocytes as homotetramers or in a heteromeric complex with
Kv7.5 subunits requires further exploration.
Expression of KCNQ genes in smooth muscle will be discussed later in
this chapter.

Biophysical properties
Outward potassium currents that are conducted through Kv7 channels
have unique biophysical characteristics. First, the threshold of activation is
approximately the same as the resting membrane voltage, usually around
-60mV. Second, when the membrane depolarizes from resting voltages, there is
a slow, voltage-dependent enhancement of the currents through the channels.
Third, the currents do not inactivate [26, 27]. These biophysical characteristics
suggest activation of Kv7 channels would oppose membrane depolarization and
decrease the excitability of excitable cells. Therefore, inhibition of these channels
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increases the likelihood of action potential firing, L-type calcium channel
activation, calcium influx, and smooth muscle contraction.
Regulation
PIP2 Mediated
Phosphatidylinositol-4,5- bisphosphate (PIP2) plays a central role in the
regulation of many voltage-sensitive potassium (Kv) channels. The Kv7 family of
potassium channels is unique in that it has been reported to require PIP 2 in order
to conduct current [28]. The best characterized of these interactions involve Mcurrent KCNQ2/KCNQ3 in expression systems [29]. Agonists of Gq/11-coupled
receptors cause M-current suppression and increase neuronal excitability. This
suppression can be attenuated by phospholipase C (PLC) inhibitors and recovery
from this suppression requires ATP [30]. Zhang and colleagues reported
evidence that PIP2 was required for activation of KCNQ channels. They reported
application of PIP2 to inside-out macropatches rescued both homomeric Kv7.2
and heteromeric Kv7.2/7.3 channel activities. Additionally, they tested the PIP 2
sensitivity of Kv7.1, Kv7.1/KCNE1, Kv7.4, and Kv7.5 and found that all of these
family members were sensitive to PIP2 since bath application of PIP2 rescued the
channel activities of all of these subtypes [31]. It has been suggested that this
increase in activation of Kv7 channels by PIP2 is the result of a PIP2-mediated
increase in the open probability of the channels. Li and colleagues reported that
each channel is differentially sensitive to PIP2 and this sensitivity is paralleled in
the differential increase in open probability of each channel subtype [32].
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Signaling Complexes
Signaling complexes have been implicated in regulating the specificity and
efficiency of signal transduction pathways [33]. Signaling complexes mediate
specificity of signaling pathways by bringing specific signaling molecules into the
proximity of specific substrates, thereby compartmentalizing signaling events.
There have been reports that Kv7 channels are involved in signaling complexes
brought together by the scaffolding protein A-kinase anchoring protein (AKAP)
79/150 in neurons. AKAP79/150 is a family of 3 orthologs: human AKAP79,
murine AKAP150, and bovine AKAP75 [34]. As its name suggests, AKAP is able
to bind protein kinase A (PKA). It is also reported to bind to protein kinase C [35],
phosphodiesterases [36], and Kv7 channels [15]. AKAP was reported to interact
with Kv7.2-7.5 channels but not Kv7.1 using fluorescence resonance energy
transfer (FRET) under total internal reflection fluorescence (TIRF) microscopy
[22].
Phosphorylation
Phosphorylation of Kv7 channels by the non-receptor tyrosine kinase, Src,
was reported to inhibit currents by reducing the open probability of the channels.
Src phosphorylation is selective for Kv7.2, Kv7.3, Kv7.2/7.3, and Kv7.5 channel
subunits [37]. The specific tyrosines phosphorylated by Src on the Kv7.3 subunit
were reported to be Y67 on the N-terminus and Y349 on the C-terminus.
Simultaneous phosphorylation of these two residues was reported to be required
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for Src regulation of the channel [38]. The physiological significance of Kv7
channel regulation by Src phosphorylation is unknown.
Transcriptional
Rose and colleagues reported transcriptional regulation of KCNQ2 in dorsal root
ganglia neurons by repressor element 1-silencing transcription factor (REST)
[39]. They reported that an upregulation of REST in situations such as
neuropathic pain and injury (typified by an overexcitability of the neurons) leads
to a downregulation of KCNQ2. This gene encodes for the Kv7.2 channel
subtype that, together with Kv7.3, form functional channels that underlie the M
current of the brain and control neuronal excitability. They showed that
application of the Kv7 channel activator, flupirtine, was able to alleviate the
neuropathic hyperalgesia in their rat model, further highlighting the importance of
Kv7 channels in neuronal excitability [39].
Pharmacology of KCNQ channels
Pharmacological agents have been developed that modulate Kv7 channel
activity. Linopirdine [DuP, 1, 3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)2Hindol-2-one] is a derivative of phenylindolinone and was developed to be a
cognitive enhancer [40]. It and its more potent analog, XE991 are effective
blockers of all five subtypes of Kv7 channels. Activators of the Kv7 channels
have been developed as well. Flupirtine [D-9998, Katadolon®, ethyl 2-amino-6((p-fluorobenzyl)amino)-3-pyridinecarbamate] is a triaminopyridine and is used
clinically as non-opioid analgesic in Europe. Modification of flupirtine’s structure
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yielded the antiepileptic drug, retigabine [also known as ezogabine in the United
States; D-23129, ethyl N-[2-amino-4-[(4-fluorophenyl) methylamino)
phenyl)carbamate]. Retigabine was reported to augment GABA-ergic signal
transduction in the central nervous system, however, it was reported to be a
much better activator of potassium channels at therapeutic ranges [41]. Both
retigabine and flupirtine activate Kv7 potassium channels Kv7.2-7.5 through
interaction with residues in the S5 and S6 pore forming domains. Kv7.1 is the
only Kv7 channel subtype that is insensitive to regulation by these Kv7 channel
activators. There exists a tryptophan residue in the S5 domain of subtypes
Kv7.2-7.5 that is critical for channel activation that Kv7.1 subunits lack that
render them unaffected by these typical pharmacological Kv7 channel activators
[42].
Kv7 channel activators like retigabine do not distinguish amongst the Kv7
channel subunits and can give rise to possible off-target effects when activating
potassium channels in tissues outside of the central nervous system. In recent
years, drugs have been developed to specifically target certain Kv7 channel
subunits over others. ICA-27243 (N-(6-chloro-pyridin-3-yl)-3, 4-difluorobenzamide) was found to be a 20-fold more potent activator of Kv7.2/7.3
heteromeric channels than of homomeric Kv7.4 channels. It was reported to have
no effect on Kv7.3 homomeric channels and only elicit weak activation of
Kv7.3/7.5 heteromeric channels.
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The only drug reported to distinguish between Kv7.4 and Kv7.5 channel
was diclofenac, an NSAID with an affinity for COX-2 similar to that of celecoxib.
Diclofenac enhanced Kv7.4 channel currents, suppressed Kv7.5 channels
currents, and produced an intermediate effect on Kv7.4/7.5 heteromeric channel
currents expressed in A7r5 cells [43]. ML213 (N-mesitybicyclo[2.2.1]heptane-2carboxamide) was a newer clinically available drug that claimed to be a selective
activator of Kv7.2 and Kv7.4. Brueggemann et al. conducted a rigorous
electrophysiological exploration of this claim by testing ML213’s effect on hKv7.4,
hKv7.5, and hKv7.4/7.5 channel currents exogenously expressed in A7r5 cells. In
contrast to what was previously reported [44], Brueggemann et al found that
ML213 robustly enhanced the currents of all three channel assemblies with no
apparent specificity. Additionally, they tested ICA-069673 (N-(6-chloropyridin-3yl)-3,4-difluorobenzamide) and found that it more effectively enhanced Kv7.4
channel currents compared to Kv7.5 channel currents but in a comparable
manner to Kv7.4/7.5 heteromeric channel currents [45]. Finding pharmacological
agents that can distinguish between the different Kv7 channel subunits is still an
important endeavor that needs to be explored further.
Channels as therapeutic targets
It is becoming increasingly clear that Kv7 modulation can be utilized as a
therapeutic target for a variety of diseases. In particular, pharmaceutical agents
can be developed to relieve ailments that involve overexcitability of the cells such
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as anxiety [46] and neuropathic pain [39], since activation of these Kv7 channels
decreases the excitability of the cells by promoting membrane hyperpolarization.
Channels in vascular smooth muscle cells
Ohya and colleagues were the first to report the existence of Kv7 channels
in vascular smooth muscle cells when they reported the expression of KCNQ1
transcripts in murine portal vein myocytes [47]. This same group then published a
follow up study where Kv7 channel blockers, linopirdine and XE991 were applied
to the portal vein and induced membrane depolarization and increased
spontaneous contractile responses [48]. These studies demonstrated the
importance of Kv7 channels and their contribution to vascular smooth muscle
membrane voltage.
Another important finding for Kv7 channels in vascular smooth muscle
cells was reported by Brueggemann et al. who isolated Kv7 currents in cultured
rat embryonic aortic smooth muscle cells (A7r5 cells). They also reported
KCNQ5 mRNA expression in both A7r5 cells as well as rat aortic smooth muscle
cells. KCNQ1 mRNA transcripts were only expressed in rat aortic smooth muscle
cells and were not expressed in A7r5 cells [49].
There have been several studies since Brueggemann et al. that
demonstrated KCNQ expression in different vascular beds such as mesenteric,
pulmonary, carotid, cerebral, aorta, and femoral artery. The general consensus of
KCNQ expression shown by these studies is KCNQ1, KCNQ4, and KCNQ5
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mRNA transcripts predominating with little to no expression of KCNQ2 or KCNQ3
[50-53].
The expression and function of Kv7 channels reported in human arteries
were found to be similar to rodent models, thus validating the role of Kv7
channels in regulating vasoconstriction and vascular tone in humans [54]. Kv7.1
channels were originally thought to only be expressed in the heart but have been
found in all human and rat myocytes studied to date. However, it is unlikely that
channels formed by Kv7.1 channel subunits contribute significantly to vascular
tone. This conclusion is based on the ability of Kv7.2-5 activator, retigabine, to
dilate pre-constricted human or rat arteries and the inability of the Kv7.1-specific
channel blocker, chromanol 293B to constrict human or rat arteries [50, 52-54].
While channels formed by Kv7.1 subunits do not contribute to resting vascular
tone, Chadha et al. reported that selective activation of Kv7.1 channels dilated
pre-constricted arteries and suggested that these channels may function under
certain conditions in VSMCs [55].
While more is being discerned about the expression and function of Kv7
channels in the vasculature, there is still much that is unknown about any
changes in expression of KCNQ during development. There has been a report,
however, that the KCNQ4 gene was downregulated in the aorta of a rat model of
hypertension which correlated to a decrease in Kv7.4 channel protein [56]. This
downregulation was not observed in the same rat model within the skeletal or left
coronary arteries [57, 58]. Mesenteric artery expression proved to be even more

17

inconsistent. Zavaritskaya and colleagues reported a reduction in levels of Kv7.4
channels within mesenteric arteries of spontaneously hypertensive rats (SHR)
relative to the same arteries from normotensive Wistar rats, but Khanamari and
colleagues did not detect any changes in KCNQ gene expression between
hypertensive and normal rats [57, 58]. Despite the lack of change detected in
mRNA levels, a reduction of Kv7.4 channel protein was reported in mesenteric
arteries of hypertensive rats [56, 57]. A reduction in Kv7.4 channel proteins has
also been reported in renal arteries of hypertensive rats [59]. In contrast to the
multiple reports of Kv7.4 expression changes in hypertensive animal models,
there is not a lot known about Kv7.5 expression in hypertension. Initial reports by
Jepps and colleagues showed an increase in KCNQ5 gene expression in
hypertension but later reports by this same group showed an insignificant
reduction of KCNQ5 gene expression. The protein levels of Kv7.5 were not
examined in either report [56, 57].
The Kv7 currents isolated from A7r5 cells and mesenteric artery myocytes
were outwardly rectifying and showed a threshold of activation around -60mV
[49, 53]. Kv7 channels activate at resting membrane voltages which is more
negative than the threshold of activation of voltage-sensitive calcium channels
(VSCCs; ~ -40mV) and promote membrane hyperpolarization which opposes
activation of VSCCs in vascular smooth muscle cells. Kv7.5 monomeric channels
are the only subtype of Kv7 channel expressed in A7r5 cells [43] and knockdown
of these channels via KCNQ5 short hairpin(sh)-RNA resulted in membrane
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depolarization which in turn, induced repetitive spontaneous Ca2+ spiking [60].
The Ca2+ spiking response was dependent on membrane depolarization and
activation of VSCCs [61]. Therefore, Kv7 channels regulate the contractile status
of VSMCs by regulation of membrane voltage which determines activation of
VSCCs.
Kv7 channel suppression has been suggested to be the mechanism
through which the hormone arginine vasopressin elicits its vasoconstrictor effects
[49, 53]. This reported suppression was dependent on the activation of protein
kinase C which is a common signaling intermediate in the Gq/11-coupled receptor
signaling pathway [49, 53]. In contrast, activation of protein kinase A has been
shown to enhance the activity of certain Kv7 channel subtypes in expression
systems [62, 63]. PKA activation is a known consequence of Gs-coupled receptor
signaling. The β-adrenergic receptor is one such Gs-coupled receptor whose
activation could potentially lead to vasodilation in VSMCs by regulation of Kv7
channels.
Phosphodiesterases
Signaling
Cyclic nucleotide concentrations within the cell are determined by the
balance between their synthesis (which is catalyzed by cyclases) and their
degradation (which is catalyzed by phosphodiesterases (PDEs)). When a
stimulatory (GαS) G-protein coupled receptor (GPCR) is activated, it goes on to
activate adenylyl cyclase, which is responsible for synthesizing cyclic adenosine
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monophosphate (cAMP). Certain PDEs degrade cAMP and thereby attenuate
cAMP-dependent cell signaling [64]. Inhibition of cAMP-specific PDEs results in
an attenuation of cAMP degradation thereby increasing the overall cellular cAMP
concentration. This increase in cAMP concentration leads to enhanced
downstream signaling of many cAMP effectors, the best characterized of which is
protein kinase A (PKA) [65]. PKA is a symmetrical complex containing two
regulatory and two catalytic subunits. Activation occurs when cAMP binds to sites
on the regulatory subunits, causing a dissociation from the catalytic subunits [66].
PKA is a serine/threonine kinase that, once activated, goes on to phosphorylate
its own downstream targets. One such target of PKA could be the Kv7 potassium
channels of interest in this thesis. This question will be addressed by later
experiments.
Characteristics
There are 11 members of the PDE family encoded by different genes [64].
Each member is able to specifically degrade cAMP, cyclic guanosine
monophosphate (cGMP), or both. The cAMP-specific isoforms of PDE in
mammals are PDE4, PDE7, and PDE8. PDE5, PDE6, and PDE9 hydrolyze
cGMP specifically, and the 5 remaining PDEs (PDE1, 2, 3, 10, and 11) can
hydrolyze both cAMP and cGMP [67]. This substrate specificity has been
suggested to be due to a glutamine residue within the catalytic site. This residue
can form hydrogen bonds with cAMP, cGMP, or both depending on its orientation
within the catalytic site and its ability to rotate [68]. Each PDE subtype has
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multiple isoforms and splice variants, which increases the difficulty in pinpointing
particular isoforms as essential contributors to specific pathological conditions
[64].
PDE4
The PDE4 family selectively hydrolyzes cAMP and is encoded by four
genes: PDE4A, PDE4B, PDE4C, and PDE4D. These genes have different
promoters which give rise to a multitude of proteins via splice variants [64]. More
than 25 human isoforms have been identified, and PDE4 is found in several
tissues including brain, lung, testis, and immune cells [67]. These PDE4 variants
are localized within tissues by protein kinase A anchoring proteins (AKAPs) [69,
70] near PKA to regulate cAMP signaling and functional responses [36]. PDE4
has been targeted in recent years for inflammatory conditions such as asthma
and chronic obstructive pulmonary disease (COPD). This exploration was based
on the findings that elevating cAMP levels within inflammatory cells inhibited their
function and that PDE4 was widely distributed within inflammatory cells and the
lung [71, 72]. Therefore, the first PDE4 inhibitors were developed to effectively
inhibit a wide range of inflammatory cell functions. This anti-inflammatory action
coupled with the ability to induce relaxation in isolated human bronchus [73]
showed promise for PDE4 inhibitors as an effective treatment for patients
suffering from asthma and COPD.
Klein and colleagues reported celecoxib, and not rofecoxib, to be a
specific inhibitor of PDE4 and PDE5. The evidence presented in that study was
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more strongly suggested that celecoxib was a cGMP-specific PDE5 inhibitor than
a cAMP-specific PDE4 inhibitor [8]. The evidence for PDE5 inhibition by this
group included celecoxib’s ability to increase coronary flow in a guinea pig
Langendorff heart, celecoxib’s ability to relax rat aortic ring preparations that
were pre-constricted with phenylephrine, an increase in cGMP levels in aortic
ring tissue in response to celecoxib treatment (as measured by an
immunoassay), and an in vitro measurement of PDE5A1 inhibition using a
recombinant human enzyme [8]. The evidence for PDE4 inhibition was not as
strong. Klein and colleagues reported that celecoxib increased cAMP levels in rat
aortic tissue 1.6-fold but that it never reached statistical significance and the data
was not shown [8]. They also reported celecoxib inhibited a recombinant human
PDE4 enzyme, but again, the data was not shown [8].
Hypertension
Hypertension is the leading risk factor for cardiovascular disease and is a
major cause of mortality [74]. About 1 in 3 American adults have high blood
pressure and only about half of all adults suffering from high blood pressure have
it under control [74]. Hypertension is characterized by chronic elevation in blood
pressure and can be classified into two categories. Primary or essential
hypertension is a chronically elevated blood pressure with no identifiable cause
while secondary hypertension is a chronically elevated blood pressure that can
be attributed to a specific cause, such as kidney disease.
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Blood pressure is directly proportional to the product of the blood flow
(cardiac output, CO) and the resistance of blood passage through precapillary
arterioles (peripheral vascular resistance, PVR) [75].
Hypertension, in general, has been associated with increased vascular
tone that results from a more depolarized membrane potential in VSMCs. This
evidence makes it clear that understanding the role of the potassium channels
that regulate VSMC membrane potential is important. To that end, there have
been reports that certain Kv7 potassium channels are downregulated in
hypertension. The Greenwood lab reported that of the 5 KCNQ genes, only
KCNQ4 was downregulated in hypertensive rats [59]. Since Kv7.4 and Kv7.5
subunits form both homo- and hetero-tetramers in the vasculature, it is possible
that the selective downregulation of KCNQ4 could lead to increased formation of
Kv7.5 homotetramers in these patients. This means drugs like celecoxib, which
activate Kv7.5 potassium channels, could prove to be therapeutically beneficial in
patients suffering from this type of hypertension.
Current Treatments
The currently used treatments for hypertension can be categorized into
four main categories: diuretics, sympathoplegic agents, direct vasodilators, and
agents that block the production/action of angiotensin. Diuretics lower blood
pressure by depleting the body of sodium and lowering blood volume.
Sympathoplegic agents reduce peripheral vascular resistance (PVR), inhibit
cardiac function, and increase venous pooling in capacitance vessels. The latter
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two actions effectively decreases cardiac output. Direct vasodilators are true to
their name and decrease blood pressure by relaxing VSMCs which causes
vasodilation in resistance vessels and could potentially increase capacitance.
Agents that block the production and/or action of angiotensin decreases PVR to
decrease blood pressure [75].
The fact that direct vasodilators are already used clinically to treat
hypertension is promising for pharmaceutical agents such as celecoxib whose
ability to activate Kv7 potassium channels directly opposes cell excitability and
results in relaxation in VSMCs. Previous research from our laboratory has
demonstrated that celecoxib can dilate mesenteric resistance arteries from rats in
vitro and in vivo [76].

CHAPTER 3
RESEARCH AIMS
In this proposal, I hypothesize that activation of the cAMP/PKA pathway is
necessary and sufficient to induce the activation of Kv7 potassium channels in
vascular smooth muscle cells. [Figure 1] To test this hypothesis I propose the
following aims:
Aim 1: Determine if PDE inhibition is sufficient to induce the
activation of Kv7 potassium channels in vascular smooth muscle
cells.
In this aim, I will utilize PDE inhibitors that are structurally different and have
different specificities for cAMP. The PDE4 (cAMP)-specific inhibitor, rolipram will
be used as a comparison to celecoxib’s effects because a previous doctoral
student, Bharath Mani, found that rolipram was able to mimic celecoxib’s ion
channel modulatory activity in the A7r5 cell line as well as its vasorelaxant effects
in pre-constricted vessels. I will also utilize the non-specific PDE inhibitor, 3isobutyl-1-methylxanthine (IBMX), in conjunction with the adenylyl cyclase
activator, forskolin, to maximally elevate cAMP levels to determine whether or not
maximal elevation of cAMP concentration is sufficient to mimic celecoxib’s Kv7
channel activation. The electrophysiology experiments will utilize cells
exogenously expressing human Kv7.4, Kv7.5 or Kv7.4/7.5 channels, since these
are the predominant channel assemblies found in the vasculature. The results of
24
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these experiments, combined with preliminary data collected from other
members of the Byron laboratory, will give a clearer answer as to whether or not
PDE inhibition is sufficient to induce Kv7 channel activation.

Aim 2: Determine whether celecoxib-induced enhancement of Kv7.5
currents is a consequence of a critical tryptophan residue on the
channel.
Celecoxib’s ability to activate Kv7.5 potassium channels in vascular smooth
muscle cells could be the result of our proposed indirect mechanism or it could
be the result of a critical tryptophan residue on the channel. Many
pharmacological Kv7 potassium channel activators act by binding directly to the
channel. For example, retigabine, the prototypical pharmacological Kv7 channel
activator, binds to a homologous site on Kv7.2, Kv7.3, Kv7.4, and Kv7.5
channels. Celecoxib was previously proposed to enhance Kv7.2 currents by
binding to the retigabine binding region, based on the loss of this effect in a
retigabine-insensitive mutant of Kv7.2, though this was not tested for Kv7.5 [77].
The retigabine binding site on Kv7.5 contains a critical tryptophan at position 235
(W235) [42]. Kv7 channel activators like retigabine bind this tryptophan residue
located in the S5 domain and stabilize the channel in an open position, allowing
increased efflux of potassium ions and membrane hyperpolarization [78]. Our
laboratory has a KCNQ5 construct that is mutated at the critical tryptophan
residue (Q5W235L), making it retigabine-insensitive [42]. If celecoxib is working
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through an indirect pathway (e.g. PDE4 inhibition or cAMP elevation) to activate
Kv7 potassium channels, then celecoxib is expected to enhance the currents of
our Q5W235L mutant. If celecoxib utilizes the retigabine binding motif on the Kv7
channels to activate them, then application of celecoxib is not expected to
enhance Q5W235L currents.
Aim 3: Determine if celecoxib-induced activation of Kv7 potassium
channels is a consequence of cAMP/PKA-dependent regulation in
vascular smooth muscle cells.
It has yet to be determined whether activation of the cAMP/PKA-dependent
pathway is necessary for celecoxib to induce Kv7 potassium channel activation.
There are inhibitors and dominant-negative analogs of the pathway’s
components that can be utilized to disrupt normal signal transduction to
determine the involvement of this pathway. Disrupting normal cAMP/PKAdependent signaling and observing the effect on celecoxib’s ability to activate
Kv7 potassium channels could aid in fully elucidating celecoxib’s mechanism of
channel activation. The inhibitor that will be utilized in this thesis work is
(9R,10S,12S)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-

1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic
acid, hexyl ester (KT5720). It is a PKA inhibitor that, when used as a
pretreatment, can prevent PKA activation by cAMP [79]. If celecoxib is activating
Kv7 channels through a cAMP/PKA dependent pathway, pretreatment with
KT5720 should attenuate the celecoxib-induced enhancement of the Kv7
currents. Additionally, using commercially available kits to determine whether or
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not celecoxib is elevating cAMP levels, as we predict, will further verify
celecoxib’s role as a PDE4 inhibitor as well as provide further evidence to help
determine whether Kv7 channel activation by celecoxib is the consequence of
this cAMP/PKA-dependent indirect signaling mechanism. The kit that will be
utilized in this thesis work is the direct cAMP ELISA by Enzo Life Sciences. More
details on this kit and the protocol used can be found in the next chapter.
Summary of Specific Aims:
Upon completion of the proposed research, the signaling mechanism
involved in celecoxib’s ability to activate Kv7 potassium channels will be better
elucidated. This will shed light on the potential differential regulation of the
different Kv7 channel subunits in the vasculature. This could lead to the
repurposing of already available drugs, like rolipram, to promote vasorelaxation.
This would also give an alternative signaling pathway to target when developing
new drugs for the purpose of promoting vasorelaxation in the vasculature. Of
course this thesis work would not be the end to the question of Kv7 channels’
sensitivity to a cAMP/PKA-dependent pathway and would, instead, act as the
starting point for a host of new scientific questions which are discussed in much
greater detail in the discussion/future directions portion of this thesis.
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Figure 1: Schematic of potential PDE involvement in Kv7 potassium channel
activation and L-type Ca2+ inhibition.

When a stimulatory (GαS) G-protein coupled receptor (GPCR) is activated, it goes
on to activate adenylyl cyclase (AC), which is responsible for synthesizing cyclic
adenosine monophosphate (cAMP) from adenosine triphosphate (ATP).
Phosphodiesterase 4(PDE4) degrades cAMP to adenosine monophosphate
(AMP) and thereby attenuates cAMP-dependent cell signaling. Inhibition of
cAMP-specific PDE4 by celecoxib results in an increase in cellular cAMP
concentration. This can lead to enhanced downstream signaling of many cAMP
effectors, one of which is protein kinase A (PKA). PKA goes on to phosphorylate
downstream targets, one of which may be Kv7 potassium channels. Activation of
Kv7 channels directly opposes the activation of voltage sensitive calcium
channels (VSCC). Both Kv7 channel activation and VSCC inhibition promote
relaxation in vascular smooth muscle cells.
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CHAPTER 4
MATERIALS AND METHODS

Cell Culture
A7r5 cells were cultured as described previously [61]. For overexpression
studies, subcultured A7r5 cells at 50-70% confluence were transfected with a
FLAG-tagged human KCNQ5 (or KCNQ4, or KCNQ4 and KCNQ5 in
combination) DNA sequence, which was inserted into a pIRES-2-enhanced
green fluorescent protein vector, using Lipofectamine (Invitrogen, Carlsbad, CA)
transfection reagent according to the manufacturer’s protocol. Confluent
subcultures of A7r5 cells were trypsinized with 0.25% trypsin +EDTA and
replated on glass coverslips. Green fluorescent protein-expressing cells were
used for electrophysiological recordings 5-10 days after transfection.

Electrophysiology
Whole cell perforated-patch configurations were used to measure
membrane currents under voltage clamp conditions in single A7r5 cells. All
experiments were performed at room temperature with continuous perfusion of
external solution. It was not necessary to distinguish between endogenous and
exogenous Kv7 currents in recordings where Kv7 channels were exogenously
29
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expressed in A7r5 cells. Exogenous Kv7 current amplitude is approximately two
orders of magnitude larger than the endogenously expressed Kv7.5 channel
currents in the A7r5 cells; therefore, any contribution from endogenous current
would be negligible [9].
The external solution for measuring Kv7 K+ currents contained (in mM): 5
KCl, 130 NaCl, 10 HEPES, 2 CaCl2, and 1.2 MgCl2. Bath solution pH was
adjusted to 7.3 using NaOH. The bath solution osmolarity was adjusted to 269272 mOsm/L using D-glucose. The internal (pipette) solution contained (in mM):
30 KCl, 110 K-gluconate, 5 HEPES, 1 K2EGTA. The internal solution pH was
adjusted to 7.2 using KOH. The internal solution osmolarity was adjusted to 268272 mOsm/L using D-glucose.
Recordings of native Kv7.5 currents in A7r5 cells required the addition of
100 μM gadolinium (III) chloride (GdCl3) in the external solution to inhibit all nonselective cation channels.
Experiments in whole-cell perforated patch configuration were started with
series resistance Rs < 30MΩ; cells with an abrupt decrease in Rs were discarded.
Voltage-clamp command potentials were generated using an Axopatch 22B
amplifier under the control of PCLAMP10 software.

cAMP Assay
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The direct cAMP ELISA kit from Enzo Life Sciences (Cat#:ADI 900-066,
Lot#:10071456D) was used. The kit is a competitive immunoassay for the
quantitative determination of cyclic AMP in cells treated with hydrochloric acid
(HCl). The optional acetylated assay format was used which provides a ~10-fold
increase in sensitivity. Standards (cAMP standard; 2000 pmol/mL) and samples
were added to wells of the provided 96-well plate per manufacturer instructions.
Individual 35mm dishes of A7r5 cells were plated at 50-100,000 cells per mL and
were serum deprived at 4pm the day before the assay was to be run. The
experiment was run per the manufacturer’s protocol with the following
modifications: Media was aspirated from each dish and washed with room
temperature Kreb’s solution instead of PBS. Kreb’s solution contained (in mM):
135 NaCl, 5.9 KCl, 1.5 CaCl2, 1.2 MgCl2, 11.6 HEPES, and 11.5 D-glucose. The
solution pH was adjusted to 7.3 using NaOH. The protocol was lengthened to
accommodate a resting period to minimize any mechanical stimulation washing
may have caused, and cell scraping, sonication, and centrifugation steps were
added to maximize the lysis of the cells and the amount of cAMP collected. The
manufacturer provided 96-well plate was used for all samples and standards and
the optical density was read in each well at 405nm on the Synergy HT plate
reader located in our laboratory. The optical densities are read in each well after
adjusting for the substrate blank, and the plate reader protocol calculates the
concentration of cAMP according to a standard curve that is generated from the
standards plated using a 4 parameter logistic (4PL) curve fitting program. The
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amount of signal read at 405 nm is indirectly proportional to the amount of
endogenous cAMP in the sample. Therefore, the more endogenous cAMP in the
sample, the more conjugated cAMP will be outcompeted for binding with the
antibody and the less yellow color will be produced when substrate is added.
Statistics
SigmaStat was used for all statistical analyses. Paired Student’s t-tests were
used when comparing any parameters before and after treatment. Comparisons
among multiple treatment groups were evaluated by analysis of variance
(ANOVA) followed by a Holm-Sidak post hoc test. Differences where p ≤ 0.05
were considered to be statistically significant.
Materials
AmpB, celecoxib, rolipram, forskolin, IBMX, and KT5720 were purchased
from Tocris Research Laboratories (United Kingdom).

CHAPTER 5
RESULTS

PDE Inhibition is Sufficient to Enhance Kv7 channel currents
Considering that celecoxib had been reported to be a PDE inhibitor [8] we
first set about determining if this action could explain the observed effect of
celecoxib on Kv7 currents. To determine if PDE inhibition is sufficient to enhance
the currents through Kv7 channels, rolipram was used in electrophysiological
studies. Bharath Mani, PhD, had previously found that rolipram, a PDE4 (cAMP
specific) inhibitor mimicked celecoxib in its ability to enhance endogenous Kv7.5
channel currents in A7r5 cells. (Not shown) He also found that rolipram mimicked
celecoxib in its ability to inhibit L-type Ca2+ channels in A7r5 cells and promote
vasodilation in vessels pre-constricted with the hormone arginine vasopressin
(AVP) [85].
As stated previously in the literature review, A7r5 cells only express Kv7.5
homo-tetramers while Kv7 channels in the vasculature can assemble as Kv7.4
homotetramers, Kv7.5 homotetramers, and Kv7.4/7.5 heterotetramers. To
determine if these channel assemblies are differentially regulated by the
PDE/cAMP/PKA pathway, I used A7r5 cells overexpressing human (h)Kv7.4,
hKv7.5, or both for electrophysiology experiments. Upon application of the PDE4
33
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Figure 2: Rolipram enhances Kv7 currents in A7r5 cells expressing human Kv7
channels. Current voltage relationship curves showing A7r5 cells expressing human
Kv7 channels before (control, black circles) and after treatment with 100nM of the PDE4
inhibitor, rolipram (white circles) (A) Mean IV curve of hKv7.4 currents showing no effect
of rolipram; n=5 (B) Mean IV curve of hKv7.4/7.5 currents showing no effect of rolipram;
n=5 (C) Mean IV curve of hKv7.5 currents showing enhancement upon treatment with
rolipram; n=5 *Significant difference between control and 100nM rolipram treatments.
Paired Student’s t-test; p<0.05, n=5 (CJ Robakowski, publication under review)
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inhibitor, rolipram (100nM), hKv7.5 currents were enhanced but hKv7.4 and
hKv7.4/7.5 currents were not affected. [Figure 2]

Furthermore, treatment of A7r5 cells with the adenylyl cyclase activator,
forskolin, in combination with the non-specific PDE inhibitor, IBMX, (10µM and
500 µM respectively) also enhanced hKv7.5 currents. Once again, hKv7.4
channel currents were unresponsive to regulation by this pathway even with the
more robust combination of an adenylyl cyclase activator with a PDE inhibitor.
However, the hetero-tetramer hKv7.4/7.5 did show a modest but significant
enhancement with forskolin/IBMX treatment and became sensitive to regulation
by the cAMP/PKA-dependent pathway with the more robust treatment
combination. [Figure 3] While it is apparent that these channel assemblies are
differentially sensitive to enhancement by PDE inhibition, it is unclear why one
treatment would affect the hetero-tetrameric channel while the other would not. It
is possible that the more robust forskolin/IBMX treatment used here produces a
larger increase in the cellular concentration of cAMP than rolipram and this larger
increase is required to elicit an effect on the less sensitive hKv7.4/7.5 channel
currents. The question regarding the amount of cAMP produced by these
different treatments is addressed later in the aim three experiments of this
section.
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Figure 3: IBMX/Fsk treatment mimics celecoxib and rolipram in Kv7.5
current enhancement. Current voltage curves of human Kv7 currents in A7r5
cells before (control, black circles) and after treatment of 500 μM of non-specific
PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX), and 10 μM of adenylyl cyclase
activator, forskolin (Fsk), (white circles) (A) Mean IV curve of hKv7.4 currents
showing no effect of IBMX/Fsk treatment. (B) Mean IV curve of hKv7.4/7.5
currents showing little enhancement with IBMX/Fsk treatment. (C) Mean IV curve
of hKv7.5 currents showing significant enhancement comparable to that seen
with celecoxib and rolipram upon IBMX/Fsk treatment *Significant difference
between control and IBMX/Fsk treatments. Paired Student’s t-test; p<0.05, n=46. (CJ Robakowski and LI Brueggemann, publication under review)

37

While rolipram and the forskolin/IBMX combination were the only
treatments I tested myself for this aim, other members of our laboratory have
collected additional data to support the hypothesis that PDE inhibition and cAMP
elevation are sufficient to enhance Kv7.5 channel currents. Bharath Mani
previously found that another non-specific PDE inhibitor, papaverine, also dosedependently (10 µM and 100 µM) enhanced endogenous Kv7.5 currents in A7r5
cells. [Figure 4] Dr. Lyubov Brueggemann found that increasing cAMP levels by
addition of 1mM Br-cAMP, a membrane-permeant cAMP analogue, enhanced
Kv7.5 channel currents in A7r5 cells. She also found that the adenylyl cyclase
activator forskolin (1 µM) was sufficient by itself to enhance Kv7.5 channel
currents. [Figure 4]
Altogether, these experiments suggest that PDE inhibition and cAMP
elevation are sufficient to activate human Kv7.5 channels, as well as rat Kv7.5
channels endogenously expressed in A7r5 cells, and this Kv7.5 channel
activation mimics the celecoxib-induced activation observed previously.

Celecoxib Requires a Critical Tryptophan Residue for Kv7.5 Channel
Activation
There are clinically available Kv7 channel activators currently on the
market. Retigabine is one such Kv7 channel activator and it is currently marketed
as an anticonvulsant. Retigabine and many other pharmacological agents
developed to activate Kv7 channels, share a common mechanism of action.
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Figure 4. Elevation of cAMP enhances endogenous Kv7.5 currents in A7r5 cells. A.
I-V relationships of endogenous Kv7.5 currents recorded in A7r5 cells before (control,
filled circles), after 15 min treatment with 1 mM 8Br-cAMP (open circles) and after 10
min of washout (filled triangles). Current were normalized to currents recorded at -20 mV
before application of 8Br-cAMP (n= 4, * indicates significant difference from control, P <
0.05, One Way Repeated Measures ANOVA). B. I-V relationships of endogenous Kv7.5
currents recorded in A7r5 cells before (control, filled circles), after 5 min treatment with 1
µM forskolin (open circles) and after 10 min of washout (filled triangles). Current were
normalized to currents recorded at -20 mV before application of forskolin (n= 4, *
indicates significant difference from control, P < 0.05, One Way Repeated Measures
ANOVA). C. I-V relationships of endogenous Kv7.5 currents recorded in A7r5 cells
before (control, filled circles), after 5 min treatment with 1 µM forskolin in the presence of
500 µM IBMX (open circles) and after 10 min of washout (filled triangles). Current were
normalized to currents recorded at -20 mV before application of forskolin/IBMX (n= 4, *
indicates significant difference from control, P < 0.05, One Way Repeated Measures
ANOVA). D. I-V relationships of endogenous Kv7.5 currents recorded in A7r5 cells
before (control, filled circles) and after treatment with papaverine (10 µM open circles,
100 µM open triangles). Current were normalized to currents recorded at -20 mV before
application of papaverine (n= 4, * indicates significant difference from control, P < 0.01,
One Way Repeated Measures ANOVA). (LI Brueggemann, publication under review)
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These agents activate Kv7 channels by binding to a critical tryptophan residue
located on the S5 pore-forming domain of the channel, thereby stabilizing its
open conformation. This critical tryptophan residue is conserved in Kv7.2 – Kv7.5
channels. On the Kv7.5 channel, the tryptophan is located at position 235.
When the tryptophan at residue 235 is mutated to a leucine (Q5W235L),
the channel is rendered retigabine-insensitive, i.e., the channel is still functional
but can no longer be regulated by retigabine or other typical pharmacological Kv7
channel activators. Our laboratory possesses this Q5W235L mutant and I used it
for the electrophysiology studies in aim 2.
First, rolipram was used as a positive control. Since it is known that
rolipram is a PDE4 inhibitor and works through the indirect cAMP/PKAdependent pathway we are trying to study, it is expected to still be able to
enhance the mutant Q5W235L channel currents. That is, in fact, what was
observed. Application of rolipram (100nM) to the retigabine-insensitive mutant
Kv7.5 channels resulted in enhancement of the currents as had been observed in
A7r5 cells expressing the wild-type Q5 channels. [Figure 5]
If celecoxib is also enhancing Kv7.5 currents through the indirect
cAMP/PKA-dependent mechanism, then it too should enhance the currents
through the Q5W235L mutant channels. However, the currents were not
enhanced upon application of celecoxib (10µM). [Figure 6] There are two
possible explanations for this result. First, it is possible that celecoxib enhances
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Kv7.5 channel currents through the critical tryptophan residue as other
pharmacological Kv7 activators do. It is also possible that celecoxib does not
produce as much of an increase in cellular cAMP levels around the channel as
rolipram does. In this case, the amount of cAMP produced in the cell after
treatment with celecoxib may be insufficient to enhance the currents of the
mutated, and therefore less sensitive, channel. This fundamental question is
addressed by experiments in aim 3.

Cellular concentrations of cAMP vary with different treatments
Troubleshooting
The cAMP ELISA proved to be a learning process. There were several
factors to consider and alter before finding a protocol that we felt produced the
most accurate results for the question we sought to address. The original
protocol, which was graciously taught to me by Dr. Abishek Tripathi in the
Majetschak lab, required our A7r5 cells to be treated in suspension and included
many spin and vortex steps. This was not ideal as A7r5 cells are normally
adherent and are mechanically sensitive. This meant that those steps where the
cells were detached and excessively handled could alter the cells’ signaling and
response to treatments. Therefore, data collected in the initial run of the assay
were disregarded. The protocol was then altered to reflect the way we handle the
cells before biochemistry experiments such as western blots and
immunoprecipitations. This prolonged the protocol by adding a 3 hour wait time
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between washing the cells and treating them so as to minimize any mechanical
stimulation before treatment. The cells were then lysed with the HCl provided in
the kit and scraping, sonicating, and centrifugation steps were added to remove
and lyse our adherent cells from their plates to collect the samples for the assay.
When troubleshooting the high variability that I experienced when I first
started running the assay, Dr. Patel brought up the excellent point HCl might not
be sufficient to lyse our cells. After reading the troubleshooting literature available
on Enzo Life Science’s website, I concluded that there are some cell lines that
are hardier than others and require longer lysing times. To determine if the 10
minute lysis time suggested in the protocol was sufficient, I used a plate of A7r5
cells and washed it as I would in my normal assay protocol. I left the cells
untreated, added the 0.1M HCl, and started a timer. I had the dish under a
microscope so I could observe lysing of the cells and any other morphological
changes in real time. This experiment revealed that the 10 minute lysis time
suggested in the protocol was sufficient for our cell line. Additionally, the cell
scraping, sonication, and centrifugation steps that we added to the protocol
should have all but guaranteed that the cells were completely lysed and cellular
contents were available for the assay.
Another issue that presented itself when using this assay was that a 15minute treatment with isoproterenol, a beta-adrenergic agonist that was expected
to stimulate adenylyl cyclase and produce cAMP to increase the cellular
concentration of cAMP, did not yield cAMP concentrations above control. To
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determine if the original treatment time (15 minutes) was not optimal, I ran a time
course using the same concentration (1 µM) of isoproterenol for 30 seconds, 1
minute, 2 minutes, 5 minutes, or 10 minutes. [Figure 7] A significant elevation of
cAMP levels were observed, with the maximal levels of cAMP produced at the 1minute time point which then steadily declined at later time points. By the 10minunte time point, cAMP levels were back to baseline, presumably due, at least
in part, to the activation of PDEs. The maximal 1-minute treatment time was used
for the remainder of the experiments unless otherwise stated.

Assay Results
To determine whether the different treatments used throughout this
thesis work produce different amounts of cAMP to elicit the differential activation
of the vascular Kv7 channels showed previously (hKv7.4, hKv7.5, and
hKv7.4/7.5) the direct cAMP ELISA from Enzo Life Sciences was used. For this
set of experiments, A7r5 cells were treated with vehicle, forskolin with IBMX,
rolipram alone, celecoxib alone, or isoproterenol alone. As expected, the robust
combination treatment of forskolin (adenylyl cyclase activator; 10 µM) and IBMX
(non-specific PDE inhibitor; 500 µM) induced a significant increase in the cAMP
concentration in A7r5 cells compared with cells treated with a DMSO vehicle
control. [Figure 8] Both rolipram alone and celecoxib alone failed to produce a
detectable change in cAMP levels compared to control. This is a reasonable
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Figure 7: Isoproterenol Time Course. Each sample of A7r5 cells (run in
duplicate) was treated with 1μM isoproterenol for various lengths of time. The
peak concentration of cAMP upon isoproterenol treatment was reached at 1
minute with the cellular levels of cAMP returning to baseline by the 10 minute
time point. To elicit the maximal effect of isoproterenol in subsequent
experiments, the 1 minute treatment time was used. n=1. (CJ Robakowski,
unpublished)
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result to obtain because there was no stimulatory step involved in those
treatments. The only cAMP to be detected in those samples would have been the
basal levels that were present in the cell at the time of treatment that were
prevented from degradation. This is consistent with the results of Klein and
colleagues, who reported that celecoxib only weakly increased cAMP levels in
the assay they used; the increase they observed never reached statistical
significance though their data was not shown [8]. In A7r5 cells, isoproterenol (1
µM) alone induced a significant increase in cAMP levels compared to control.
[Figure 8] This was expected, as isoproterenol is a beta-adrenergic agonist and
should stimulate adenylyl cyclase activity to produce cAMP. Since neither
celecoxib or rolipram alone produced a detectable change in cAMP levels,
isoproterenol (1 µM) was administered simultaneously with either celecoxib or
rolipram (10 µM or 100 nM respectively) with the rationale that stimulating cAMP
production while inhibiting its degradation by PDE4 is likely to result in a higher
overall concentration of cAMP than with isoproterenol alone. However, results
were variable and even after repeating the experiment six times, isoproterenol in
combination with either rolipram or celecoxib was not statistically different from
isoproterenol alone. [Figure 9] It is possible that the short (1 minute),
simultaneous treatment of the cells with isoproterenol along with celecoxib or
rolipram did not provide sufficient time for celecoxib or rolipram to inhibit PDE4
and cAMP degradation before the treatment was stopped and the cells were
lysed. To determine if the lack of change observed between the treatments was
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Figure 8: cAMP is elevated to different concentrations with different
treatments. cAMP levels are very significantly and consistently increased upon
combination treatment of forskolin with IBMX. PDE4 inhibitors, rolipram and
celecoxib, do not significantly elevate cAMP concentrations alone. Isoproterenol
(1μM) is able to significantly increase cAMP levels. *Significant difference by
independent t-test compared to control; p<0.05, n=3-10. **Significant difference
between control and Fsk/IBMX treatments; independent t-test, p<0.01, n=5-10.
(CJ Robakowski, unpublished)
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due to insufficient time, the assay was repeated and the treatment times were
altered. Cells were treated with celecoxib or rolipram (10 µM or 100 nM
respectively) five minutes prior to isoproterenol treatment. Isoproterenol (1 µM)
was then added to the cells for 15 minutes. Previously, 15-minute isoproterenol
treatments yielded cAMP levels that were comparable to baseline. [Figure 9] This
is assumed to be due to the activation of PDEs. The rationale behind this new
time course was that celecoxib and rolipram would have more time to elicit their
inhibitory effects on PDE4 and prevent cAMP degradation before stimulation of
cAMP production by an agonist occurred. Ideally, the addition of celecoxib or
rolipram as a pretreatment would prevent the time-dependent degradation of
cAMP observed with isoproterenol alone and would reveal differences in the
effectiveness of celecoxib and rolipram to prevent cAMP degradation. The results
of the celecoxib or rolipram pretreatment experiments were inconclusive. With
only an n of 3 for both celecoxib and rolipram as pretreatments, the results were
highly variable. Rolipram pretreatment before isoproterenol stimulation trended
toward preventing the cAMP degradation that is observed between the 1- and
15-minute time points with isoproterenol alone. [Figure 9] Celecoxib pretreatment
before isoproterenol stimulation did not suggest a prevention of cAMP
degradation based on its trend.
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Figure 9: Celecoxib does not prevent cAMP degradation. cAMP levels return
to baseline after treatment with 1μM isoproterenol (ISO,15min) . Simultaneous
treatment with a PDE4 inhibitor (rolipram, 100nM or celecoxib, 10μM) did not
significantly increase cAMP levels with isoproterenol compared to isoproterenol
alone. Only pretreatment with rolipram (100nM) prevented degradation of cAMP
after isoproterenol treatment though it did not reach statistical significance.
Celecoxib (10μM) treatment suggested an inability to prevent cAMP degradation
when used as a pretreatment in cells later treated with isoproterenol. *Significant
difference by independent t-test compared to control; p<0.05, n=3-10.
#Significant difference between ISO alone at 1 minute and ISO alone at 15
minutes; independent t-test, p<0.05, n=4-6. (CJ Robakowski, unpublished)
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In summary, the results of this assay demonstrate that there is indeed a
difference in the cellular concentrations of cAMP present after different
treatments are administered. It is especially clear for the forskolin (10 µM) and
IBMX (500 µM) combination treatment as it consistently produced a very
significant (p<0.005) increase in cAMP concentration compared to the control.
[Figure 8] These differences in the amount of cAMP generated with each
treatment can provide a possible explanation as to why the forskolin/IBMX
combination treatment enhanced the typically less sensitive hetero-tetrameric
hKv7.4/7.5 channel currents while rolipram treatment did not.

PKA activation is involved in celecoxib-induced Kv7 channel activation
In order to determine if PKA activation is involved in celecoxib-induced
Kv7 channel activation, I utilized a PKA inhibitor, KT5720. This drug, when used
as a pretreatment, should inhibit the activation of PKA [79] thus attenuating any
downstream signaling, such as PKA-dependent channel activation. As a control,
rolipram (100nM) was used. When cells were pretreated with KT5720 for 30
minutes, the endogenous Kv7.5 channel current enhancement normally elicited
by rolipram was completely attenuated compared to vehicle control. [Figure 10]
If celecoxib is activating endogenous Kv7.5 channel currents in a PKAdependent manner, then KT5720 pretreatment should also attenuate any
celecoxib-induced enhancement of Kv7.5 currents. Interestingly, KT5720
pretreatment (30minutes) did attenuate the celecoxib-induced enhancement of
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Kv7.5 current relative to vehicle controls. [Figure 11] This suggests that celecoxib
could, at least partially, require PKA activation to elicit its Kv7 channel activation.
Further experiments will have to be completed to definitively implicate PKA
activation in celecoxib-induced Kv7 channel enhancement and will be discussed
in the future directions of this thesis.
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CHAPTER 6
DISCUSSION
This thesis work sought to uncover the mechanism through which
celecoxib enhances Kv7 currents, which was proposed to be the reason behind
its safer cardiovascular risk profile. To determine if phosphodiesterase inhibition
was the mechanism by which celecoxib elicits Kv7 channel activation, I sought to
answer three main questions: 1.) Is PDE inhibition sufficient to enhance Kv7
currents? 2.) Is PKA activation necessary for Kv7 current enhancement? 3.)
Does celecoxib enhance Kv7 currents through a critical residue that is typical of
other pharmacological Kv7 channel activators?
The data reported in chapter 5 suggest that PDE inhibition is in fact
sufficient to enhance Kv7.5 channel currents. More importantly, the data revealed
that different Kv7 channel subunit assemblies are differentially sensitive to
regulation by the cAMP/PKA-dependent pathway being studied. This is important
from a physiological standpoint because it provides insight into whether or not
certain drugs would be efficacious in the vasculature. By using structurally
different PDE inhibitors with different specificities for cAMP, I was able to mimic
celecoxib’s ability to increase Kv7.5 currents as well as determine a treatment
that was able to enhance the physiologically relevant and typically less sensitive

53

54

hKv7.4/7.5 hetero-tetrameric channel currents (10 µM forskolin/500 µM IBMX
combination).
Utilizing the direct cAMP ELISA, I was able to gain insight into the
differential regulation of different channel assemblies by the cAMP/PKAdependent pathway. The results from this assay revealed that there is a
difference in the cellular concentration of cAMP following treatment of A7r5 cells.
Forskolin and IBMX most significantly increased cAMP levels compared to
control, and there was no detectable change in cAMP levels upon treatment with
rolipram or celecoxib. This suggests that the larger increase in cAMP levels
produced by the combination treatment of forskolin and IBMX could be
responsible for the enhancement of the less sensitive heteromeric hKv7.4/7.5
channel currents that is not mimicked with rolipram treatment.
The ELISA data also brought to light the fact that celecoxib may be a
weak PDE4 inhibitor at best. The hypothesis that celecoxib was a PDE4 inhibitor
and was utilizing a cAMP/PKA-dependent pathway to activate Kv7 channels was
developed after Klein et al reported celecoxib to increase both cGMP and cAMP
levels in isolated rat aorta tissue. [8] However, Klein and colleagues never
actually show the cAMP-specific data and simply state that celecoxib produced a
weak, 1.6-fold increase in cAMP levels and that it did not reach statistical
significance. [8] So while it was interesting to find the Kv7.4 and Kv7.5 channel
subunits were differentially sensitive to regulation by a cAMP/PKA dependent
pathway, it may not be the mechanism through which celecoxib is eliciting its Kv7
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channel activation. It could turn out that celecoxib only activates the channel
through its critical tryptophan residue just like retigabine and other Kv7 channel
modulators.
Electrophysiology experiments that utilized the PKA inhibitor, KT5720,
offered perspective on the involvement of the cAMP/PKA pathway on Kv7.5
channel current enhancement. As expected, rolipram-induced Kv7.5 current
enhancement was attenuated when cells were pretreated with KT5720, which
inhibits activation of PKA. Interestingly, pretreatment of A7r5 cells with KT5720
also prevented celecoxib-induced Kv7.5 current enhancement. This was
interesting considering the data in which celecoxib was unable to enhance the
mutant Kv7.5 channel currents suggested requirement of the critical tryptophan
residue for celecoxib-induced enhancement of the channel. This was also
interesting considering the preliminary cAMP ELISA data suggested celecoxib
was unable to prevent the degradation of cAMP produced after isoproterenol
treatment and did not show any detectable elevation in cAMP levels when used
as a treatment on its own. There have been reports that PKA inhibitors KT5720
and H89 have many non-specific targets that effect many different signaling
pathways and are not a reliable indication of PKA involvement on their own [80].
A more accurate way to implicate PKA involvement in a specific signaling event,
as we are attempting to do, would require the combination use of KT5720 with a
protein kinase inhibitor peptide or a more specific molecular method such as
RNA interference (RNAi) [81]. Directly measuring PKA activity in response to
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celecoxib treatment would also better implicate the necessity of PKA activation
for celecoxib-induced current enhancement. This further validates the need for
future exploration into the exact mechanism of celecoxib.
While I originally sought to determine whether or not PDE inhibition/cAMP
elevation is necessary for celecoxib-induced Kv7 channel activation, with the
data discussed above, I cannot draw that conclusion. This is due to the fact that
PKA activation, the assumed downstream effect of PDE inhibition/cAMP
elevation, was only shown to be potentially involved in celecoxib-induced Kv7
channel activation and in fact, data from the mutant channel experiments lends
more evidence to celecoxib requiring the critical tryptophan residue to elicit its
effect. Additionally, the cAMP ELISA data was inconclusive as to whether or not
celecoxib elevated cAMP levels either on its own or in combination with a
stimulus such as isoproterenol. Given the inconclusive nature of the data
discussed, further work must be completed before PDE inhibition/cAMP
elevation’s necessity in celecoxib-induced Kv7 channel activation can be
concluded. As it stands, the data suggest multiple possible mechanisms by which
celecoxib could be eliciting its Kv7 channel activation with better evidence
suggesting requirement of the critical residue for channel activation than an
indirect PDE4/cAMP/PKA-dependent pathway.
Protein kinase A anchoring proteins add another layer of complexity to
celecoxib’s mechanism of Kv7 channel modulation. It is worth noting that PKA
anchoring proteins offer cAMP signaling specificity by placing PKA in proximity to
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specific substrates and effectors [82]. AKAP 79/150, in particular, has been
reported to be an important component of PKA and PKC-mediated
phosphorylation of other ion channels [83]. AKAPs position PKA in close spatial
proximity to specific substrates that allow a localized increase in cAMP to confine
PKA phosphorylation to that specific subset of substrates. It is still unknown,
however, if localized or global increases in cAMP are responsible for the cAMPdependent enhancement of Kv7.5 currents that we have observed in this study,
and we have yet to explore any role of AKAP in our present findings. It could be
worth exploring this role as detailed in the future directions portion of this thesis.
Recently, the Greenwood lab published an article reporting Kv7.4 channel
activation by the heterotrimeric G-protein βγ subunits [84]. In that report,
Greenwood and colleagues reported that β-AR-Gβγ subunit signaling activates
Kv7.4 channels in HEK cells heterologously expressing Kv7.4 and in rat renal
artery myocytes. They reported that G-protein βγ subunits enhanced the open
probability of Kv7.4 channels and gallein, an inhibitor of Gβγ subunits, prevented
stimulatory effects. Only Kv7.4 channel activity was explored, however [84]. And
as stated previously, Kv7.4 and Kv7.5 predominantly form heterotetramers in the
vasculature. Since effects on Kv7.5 and Kv7.4/7.5 channels activities were not
explored in that report, it is unclear whether β-AR-Gβγ subunit signaling is
relevant physiologically. Results from our laboratory (Mani et al., manuscript
submitted) do not reproduce the enhancement of Kv7.4 currents by isoproterenol
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reported by Stott et al., though our results are based on expression of Kv7.4 in
A7r5 cells rather than HEK cells. However, it’s possible that the β-AR activation
could mediate vasodilatory responses by activating different Kv7 channel
subunits through diverse signaling molecules.
Lastly, it is unclear what, if any, structural differences between celecoxib
and rofecoxib are responsible for the difference in their ability to activate Kv7
channels. The sulfone group of rofecoxib (which is a sulfonamide in celecoxib) is
what allows rofecoxib to be more specific for COX-2 than celecoxib [2]. But since
we concluded that the Kv7 channel activation by celecoxib is independent of its
COX-2 inhibitory activity, it is unclear of those different groups play a role in Kv7
channel activation. There are a few other noteworthy difference between
rofecoxib and celecoxib. Rofecoxib contains a furanone heterocycle and contains
no fluorine or additional groups on its aromatic ring [2]. Celecoxib contains a
pyrazole heterocycle with a tri-fluorinated carbon as well as a methyl group on its
aromatic ring [2]. Any of these structural differences could be responsible for the
difference in celecoxib and rofecoxib’s abilities to activate the Kv7 channels but
that has not yet been explored.

CHAPTER 7
FUTURE DIRECTIONS
PKA Phosphorylation Studies
From the data collected, it is clear that at least the Kv7.5 subunits are
sensitive to a cAMP/PKA-dependent pathway. First, it would be beneficial to
determine if treatment with celecoxib affects PKA activation. This could be done
using cell lysates with fluorescence based assays like those detailed by Shults
and colleagues in Nature Methods [86]. Normally when PKA is activated, it goes
on to phosphorylate and activate many downstream effectors. It would also be
helpful to investigate whether or not there is a phosphorylation of the Kv7.5
channel associated with its activation by PKA. Using MIT scansite software, 11
putative PKA phosphorylation sites exist within the Kv7.5 amino acid sequence.
These sites exist both on the N-terminus and C-terminus of the channel. Our
laboratory has attempted to create mutant channels with either the C or Nterminus truncated to determine which residues are important for PKA regulation,
but those mutants never resulted in functional channels. A strategy that could be
employed to answer the question as to which, if any, residue(s) is necessary for
PKA regulation would be to construct point mutations of candidate
phosphorylation sites to render the protein unphosphorylatable at these sites.
Each potential residue could be point mutated and electrophysiology experiments
59
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could be run to determine the functional necessity of each of the potential PKA
residues. Once this residue is determined, further studies can be done to assess
whether that phosphorylation site can be exploited therapeutically. This is also
important information to have because we reported that different Kv7 subunits
are differentially regulated by this PKA pathway and some, like Kv7.4, are
seemingly insensitive to PKA regulation. Using the same MIT scansite software,
only three putative PKA phosphorylation sites were identified in the Kv7.4
sequence. Of those three sites, only two corresponded to analogous amino acid
sequences in the Kv7.5 channel. The fact that there are so many more potential
PKA phosphorylation sites on the Kv7.5 channel and so few on the Kv7.4
channel could explain the differences in sensitivity to PKA regulation between the
two subunits.
Revisit cGMP Pathway
The Klein paper that reported celecoxib to be a PDE inhibitor reported that
celecoxib, and not rofecoxib, was both a PDE4 (cAMP-specific
phosphodiesterase) and a PDE5 (cGMP-specific phosphodiesterase) inhibitor
and their evidence for PDE5 inhibition was much stronger than for PDE4
inhibition [8]. Inhibition of PDE5 would result in higher levels of cGMP and the
cGMP-NO pathway is a well-defined vasodilatory pathway so it may be worth
revisiting. Electrophysiology experiments could be repeated with a PDE5
inhibitor, such as tadalafil or sildenafil, to see if they, too, mimic celecoxib’s ion
channel modulatory activity. There is also a chance that there is significant cross-
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talk between the cAMP and cGMP pathways that could further complicate the
mechanism of Kv7 channel current enhancement that we report here. If it turns
out that PDE5 inhibition mimics the Kv7.5 current enhancement seen with PDE4
inhibitors, there also exist PKG inhibitors that could be used as a pretreatment in
the A7r5 cells similar to the experiment I showed previously using PKA inhibitor,
KT5720. The PKG inhibitor, KT5823, works in much the same way and would
attenuate any cGMP-induced Kv7 current enhancement when used as a
pretreatment in the cells. Electrophysiology experiments utilizing KT5823 would
give insight into the necessity of the cGMP pathway in celecoxib’s Kv7 channel
activation. It would also be interesting to replicate Klein et al.’s reported
celecoxib-induced increase in cGMP levels using an ELISA kit akin to the direct
cAMP ELISA kit used in this thesis work. Klein et al stated that PDE5 inhibition
was more important than PDE4 inhibition to the vasodilatory effect exhibited by
celecoxib in their experiments and it would be interesting to see if the same trend
was present in our hands.
DMC as a PDE inhibitor
Our laboratory previously reported that celecoxib’s ion channel modulatory
activity was independent of its COX-2 inhibitory activity. This conclusion was
drawn after dimethyl celecoxib (DMC) a structural analogue of celecoxib that
lacks any COX-2 inhibitory activity, was able to mimic celecoxib in its ability to
enhance Kv7 channel currents as well as inhibit L-type calcium channel currents.
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Furthermore, rofecoxib, which has an even higher affinity for COX-2 than
celecoxib, was unable to mimic either of these ion channel modulatory effects.
It would be interesting to explore whether DMC also mimicked celecoxib’s
ability to inhibit PDE4 or PDE5. Literature searches yielded no studies in which
this specific effect was studied for DMC. If it turns out that DMC also inhibits
PDE4 and/or PDE5 activity, it could lead to insight regarding celecoxib’s
mechanism of Kv7 current enhancement. For instance, if DMC is found to be a
PDE4 inhibitor but not a PDE5 inhibitor, it could lend more support to the
cAMP/PKA mechanism for Kv7 channel regulation. If DMC is a PDE5 inhibitor as
well, it would support the need to revisit the cGMP pathway and its potential
effect on the Kv7 enhancement we have observed previously.
AKAP
As discussed in the previous chapter, anchoring proteins are important for
bringing signaling components in close proximity to the substrates they target.
AKAPs allow for PKA signaling to be determined by the specific pools of cAMP
within their vicinity, thus distinguishing between different pools of cAMP within
the cell. AKAPs have been reported to bring PKA, PDEs, and substrates such as
ion channels together to promote targeted signaling. It has yet to be determined if
any anchoring proteins play a role in celecoxib’s mechanism of Kv7 channel
activation. It would be worth exploring if there exists a signaling complex that
brought together the Kv7 channels of interest with PKA and PDE4. To explore
this, experiments would have to be run to determine if any of those signaling
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components are in close proximity which could provide insight into the possibility
of a signaling complex being involved in celecoxib’s mechanism of Kv7 channel
activation. Our laboratory found previously that AKAP150 co-immunoprecipitates
with the Kv7.5 channel in A7r5 cells [unpublished]. It has yet to be explored
whether PDE4 or PDE5 are also present in those immunoprecipitates. Proximity
ligation assays might be a better method for exploring our direct protein-protein
interactions of interest.
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